{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:37:32Z","timestamp":1761748652999,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.acvd.2012.06.001","type":"journal-article","created":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T21:01:20Z","timestamp":1349298080000},"page":"587-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: The CLO-CLO trial"],"prefix":"10.1016","volume":"105","author":[{"given":"Markus","family":"Oberh\u00e4nsli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serban","family":"Puricel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Togni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Baeriswyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2012.06.001_bib0005","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ahj.2007.12.014","volume":"155","author":"Casterella","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2012.06.001_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","volume":"117","author":"King","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2012.06.001_bib0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJMe038191","article-title":"Antiplatelet therapy for ischemic heart disease","volume":"350","author":"Lange","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2012.06.001_bib0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2012.06.001_bib0025","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2012.06.001_bib0030","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of chest physicians evidence-based clinical practice guidelines (8th ed.)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2012.06.001_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","article-title":"Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment","volume":"99","author":"Sibbing","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2012.06.001_bib0040","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2012.06.001_bib0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.thromres.2006.08.012","article-title":"Clopidogrel resistance?","volume":"120","author":"Gurbel","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2012.06.001_bib0050","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2012.06.001_bib0055","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","article-title":"Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2012.06.001_bib0060","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinthera.2009.04.017","article-title":"Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects","volume":"31","author":"Kim","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.acvd.2012.06.001_bib0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00392-009-0033-1","article-title":"Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study","volume":"98","author":"Neubauer","year":"2009","journal-title":"Clin Res Cardiol"},{"issue":"66","key":"10.1016\/j.acvd.2012.06.001_bib0070","first-page":"e9","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2012.06.001_bib0075","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1160\/TH08-05-0313","article-title":"Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease","volume":"100","author":"Braun","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2012.06.001_bib0080","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur Heart J"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213612001921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213612001921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:40:35Z","timestamp":1761745235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213612001921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1875213612001921"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2012.06.001","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: The CLO-CLO trial","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2012.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}